BioScrip Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Jefferies Resumes BioScrip (BIOS) at Buy
November 8, 2016 7:22 AM ESTJefferies resumes coverage on BioScrip (NASDAQ: BIOS) with a Buy rating and a price target of $2.50.
Analyst Brian Tanquilut commented, "We were surprised by BIOS's disappointing Q3 and the resulting guidance cut, and recognize that it further dents the company's already-weak credibility... More
BioScrip (BIOS) Misses Q3 EPS by 7c
November 7, 2016 5:19 PM ESTBioScrip (NASDAQ: BIOS) reported Q3 EPS of ($0.12), $0.07 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $224.5 million versus the consensus estimate of $223.26 million.
The Company reconfirms its plan to achieve between $14 million to $17 million in Home Solutions cost synergies... More
